Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension

Trial Profile

Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2013

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 02 Jul 2013 Last checked against ClinicalTrials.gov record (extension study NCT01610713).
    • 02 Jul 2013 Last checked against ClinicalTrials.gov record (extension study NCT01610713).
    • 02 Jul 2013 Last checked against ClinicalTrials.gov record (extension study NCT01610713).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top